OT mobile menu

Search form


Bryant Furlow

Bryant Furlow

Posts by Author

The emergence of ibrutinib-resistant chronic lymphocytic leukemia (CLL) can be detected prior to clinical relapse, according to an analysis of patients from four ibrutinib trials.

ERBB2/HER2 mutations appear to be rare but targetable oncogenic drivers in non-small cell lung cancer, according to findings from a small retrospective cohort records analysis.

An IHC assay for ALK status in non-small cell lung cancer tumor tissue predicts crizotinib treatment outcomes and offers a rapid and potentially less expensive alternative to older FISH ALK status assays.

Antibiotics administered less than a month before initiation of immunotherapies for patients with advanced kidney cancer might impair tumor control, according to a retrospective analysis.

Despite significant toxicities, idelalisib improved time to progression for patients with treatment-resistant chronic lymphoblastic leukemia.

Combined miniCHOP and treatment with the fully-human anti-CD20 monoclonal antibody ofatumumab is associated with improved overall survival among elderly patients diagnosed with diffuse large B-cell lymphoma.

Stem cells that give rise to acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) express higher levels of the CD99 cell surface protein-sugar molecule than normal stem cells.

Many childhood brain tumors harbor potentially targetable gene mutations, according to a prospective single-institution study of more than 200 tumor samples, researchers reported in the journal Neuro-Oncology.

Dietary fat intake might promote the growth of melanoma tumors harboring BRAF V600E mutations, and lipid-lowering drugs can slow that growth, according to a mouse study.

Among active or former smokers undergoing lung cancer screening, longer peripheral leukocyte telomere length is associated with an increased risk of lung cancer.


By clicking Accept, you agree to become a member of the UBM Medica Community.